Baricitinib
Sign in to save this workspacePrimary targets: JAK1, JAK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
97.99
Gini
0.616
CATDS
0.014
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Baricitinib. Strongest target: STK38L_NDR2 at 99.4% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | STK38L_NDR2 | 99.4% | 0.6% |
| 2 | JAK1 | 98.1% | 1.9% |
| 3 | TYK2 | 97.3% | 2.7% |
| 4 | JAK2 | 97.2% | 2.8% |
| 5 | STK38_NDR1 | 97.1% | 2.9% |
| 6 | JAK3 | 97.0% | 3.0% |
| 7 | STK22D_TSSK1 | 91.7% | 8.3% |
| 8 | PKA | 90.9% | 9.1% |
| 9 | PKCG | 88.2% | 11.8% |
| 10 | LATS1 | 86.4% | 13.6% |
| 11 | CAMK2D | 82.2% | 17.8% |
| 12 | DAPK1 | 81.9% | 18.1% |
| 13 | ROCK1 | 81.7% | 18.3% |
| 14 | DMPK2 | 81.2% | 18.9% |
| 15 | PKACB | 80.3% | 19.7% |
| 16 | PKACG | 79.9% | 20.1% |
| 17 | ACK1 | 79.5% | 20.5% |
| 18 | PKCD | 76.9% | 23.1% |
| 19 | ROCK2 | 76.5% | 23.5% |
| 20 | P70S6K_RPS6KB1 | 74.7% | 25.3% |
Selectivity landscape
Where Baricitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Baricitinib.
Annotations
Sign in to read and post annotations.
Loading…